New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.
